Sapu BioScience Highlights TGFB2-Guided Strategy to Enhance Taxane Therapies, Reinforcing the Rationale for Sapu-001
San Diego, CA, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sapu BioScience today…
Sapu Nanos Sapu003 Advances to Human Clinical Testing – Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients
Sapu003 Designed to Overcome Limitations of Afinitor®, FDA-Approved Oral Everolimus, Delivering Full…
